EpiSign

Greenwood Diagnostic Laboratories in partnership with London Health Science Centre present EpiSign!

GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes
GGC Launches EpiSign, a Novel Clinical Test for Epigenetic Changes

EpiSign is an assay designed to readily identify proven and reproducible epigenetic signatures by assessing genome-wide methylation.

EpiSign has multiple applications in the clinical setting by providing an additional diagnostic tool beyond the current sequencing and copy number technology paradigm.  EpiSign can detect multiple methylation abnormalities associated with certain imprinting or triplet repeat conditions. This test can also identify disease-specific methylation patterns involving multiple loci across the genome. 

Assessment of these distinct methylation patterns can be a useful screening tool for these disorders in the diagnostic work-up or can be applied in a more targeted fashion to help resolve variants of uncertain clinical significance.

Version 3 launched in June 2021 increasing the number to more than 50 identifiable disorders.


One Assay. Two Options.

Episign is offered as two different tests to suit the needs of your patient.

  • EpiSign Complete v.3
    A comprehensive analysis including 50 disorders.
  • EpiSign Variant   
    A targeted review of the methylation data intended to resolve variants of uncertain clinical signficance. 

Meet The Jones Family

The journey to becoming parents did not start as an easy one for my husband and I. We suffered the heartache of miscarriage and the unimaginable pain of burying our first born child. Our son, sweet 1 lb 1.4 ounce, 12 inches long, teeny, tiny little Joseph “Hamilton” Jones was born with spina bifida, hydrocephalus, and a heart defect. It tore our hearts out leaving the hospital without him, knowing our dreams and hope for the future were shattered....

In The News